Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting millions globally.
• Progressive cyst growth leads to kidney function deterioration and end-stage renal disease.
• Traditional management focused on conservative measures like blood pressure and water balance control.

Purpose of the Study:

• To review current management strategies for ADPKD, focusing on blood pressure and water balance.
• To discuss the role of disease-modifying drugs, specifically Tolvaptan, in ADPKD treatment.
• To highlight the pathogenesis of hypertension and the mechanism of Tolvaptan in ADPKD.

Main Methods:

• Review of current literature on ADPKD management.
• Analysis of the pathogenesis of hypertension in ADPKD.
• Explanation of Tolvaptan's mechanism of action and its effects on cyst growth and renal function.
• Discussion of potential adverse effects of Tolvaptan on water and sodium balance.

Main Results:

• Hypertension is a key feature in ADPKD, requiring specific management plans.
• Tolvaptan, a vasopressin V2 receptor antagonist, inhibits cyclic adenosine monophosphate, attenuates cyst growth, and delays renal failure in patients with large kidneys.
• Understanding water and sodium balance is critical for managing ADPKD and Tolvaptan therapy.

Conclusions:

• A new paradigm in ADPKD management involves disease-modifying drugs like Tolvaptan.
• Effective blood pressure control and careful management of water balance are essential for patients with ADPKD.
• Tolvaptan offers a promising therapeutic option for slowing ADPKD progression, but requires monitoring for side effects.